Ang-II serves as a proinflammatory mediator between hypertension and neuroinflammation.12 The therapeutic viability of using the antihypertensives angiotensin receptor blockers (ARBs) is likely fruitful given that preclinical studies in AD mouse models have shown the attenuation of cerebrovascular and neurological deficits due to ARB administration.56 Patients with mild-to-moderate AD treated with losartan (ARB) demonstrated no differences between cohorts in brain volume loss, white matter hyperintensities and cognitive assessments. This evidence concerns the gene AGT and Alzheimer disease.